 |
|
|
| |
The prevalence of hepatitis C virus NS5A polymorphisms in Europe
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Stephanie Popping1 (S.Popping@erasmusmc.nl), Valeria Cento2, Annemarie Wensing3,5, Carole Seguin-Devaux4,5, Charles A. Boucher1,5, Bart Rijnders9, Milosz Parczewski 5,6, Anna Urbanska6, Mario Poljak 5,7, Maja Lunar5,7,Adolfo de Salazar8, Marianna Aragri2, David A.M.C. van de Vijver 1,5, *Federico García, 5,8, *Francesca Ceccherini-Silberstein5,10, on behalf of the HEPVIR working group of the European Society for translational antiviral research (ESAR). * Equally contributing authors.
1. Erasmus MC, Rotterdam, Department of Viroscience, 2. University of Milan , Milan, Department of Experimental Medicine and Surgery, 3. Clinical Virology, Medical Microbiology, University Medical Center Utrecht, The Netherlands, 4. Luxembourg Institute of Health, Luxembourg, Department of Infection and Immunity Eschsur AlzetteLuxembourg, 5. The European Society for translational Antiviral Research, Utrecht, The Netherlands, 6. Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Poland, 7. Institute of Microbiology and Immunology, University of Ljubljana, Slovenia, 8. Hospital UniversitarioSan Cecilio, InstitutoBioanitarioIbs.Granada, Department of Clinical Microbiology & Infectious Diseases, Spain, 9. Erasmus MC, University Medical Center Rotterdam, Internal medicine and infectious diseases department, the Netherlands , 10. University of Rome Tor Vergata, Rome, Department of Experimental Medicine and Surgery.
|
| |
|
|
|
|
|
